Drug Trial Radar · NCT06132828
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
216
Planned (sponsor's estimate)
Start
Nov 27, 2023
Primary completion
Jul 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Zhejiang Doer Biologics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors
Conditions
- Solid Tumor
Interventions
DR30206Drug
Subjects receive DR30206 intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- PartA: Incidence of dose limiting toxicities (DLTs)Time frame: 21 days following first dose
- PartA: Maximum tolerated dose (MTD)Time frame: 21 days following first dose
- PartA: Recommend dose of expansion(RDE)Time frame: 21 days following first dose
- PartA+B: Adverse evens (AEs)Time frame: Up to 90 days after last dose
- PartA+B: Serious adverse evens (SAEs)Time frame: Up to 90 days after last dose
- PartB: Objective response rate (ORR)Time frame: Up to approximately 12 months
- PartB: Recommended phase 2 dose (RP2D)Time frame: 21 days following first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.